CC-486 Treatment of Acute Myeloid Leukemia: FDA Grants Priority Review

Bristol Myers Squibb recently said the FDA has granted CC-486 priority review rights for the treatment of acute myeloid leukemia (AML) in adultsThe award was based on the results of the QuaZAR AML-001 study phase III, which was presented at the Annual Meeting of the American Society of Hematology (ASH) in December last year: The overall survival (primary endpoint) of patients in the CC-486 treatment group was significantly higher than in the placebo groupAfter about 3.5 years of median follow-up, the total survival (OS) in the CC-486 treatment group was 24.7 months and the placebo group OS was 14.8 months"Patients with remission are looking for treatment options that reduce the likelihood of recurrence and extend total survival, and we believe CC-486 can deliver clinical benefits for these patients," said Noah Berkowitz, head of global clinical development at the'sBristol Myers Squibb2019, Bristol Myers Squibb acquired CC-486 for CelgeneCC-486 is an oral secondary methylated agent that can be integrated into DNA and RNA